This 2017 systematic review evaluated the efficacy of off-label augmentation strategies in unipolar depression by analyzing data from meta-analyses, randomized controlled trials, and case studies. The review identified five agents—modafinil, ketamine, pindolol, estrogen, and testosterone (in hormone-deficient patients)—with evidence supporting their clinical effectiveness when added to antidepressant regimens. Other agents
